New Test Could Help Pinpoint IBD Diagnosis, Study Finds

Why It Matters

A more accurate stool‑based test can lower diagnostic costs, speed patient pathways, and support personalized IBD therapy, reshaping the gastro‑enterology market.

Key Takeaways

• Luminescent reporter measures granzyme A activity in stool
• Test outperforms calprotectin alone in 150‑sample study
• Enables faster, non‑invasive IBD diagnosis and monitoring
• Spinout IDXSense aims to commercialize the technology
• Could support personalized treatment response tracking

Pulse Analysis

Inflammatory bowel disease remains a diagnostic challenge because clinicians rely heavily on colonoscopy, an invasive, expensive procedure, and on generic stool markers like calprotectin that lack disease specificity. As healthcare systems push for cost‑effective, patient‑friendly solutions, the demand for precise, non‑invasive biomarkers has intensified. A test that can pinpoint gut‑specific inflammation without endoscopy would not only accelerate diagnosis but also improve disease monitoring, a critical need for chronic conditions where treatment adjustments are frequent.

The breakthrough centers on granzyme A, an enzyme released by overactive T‑cells in inflamed intestinal tissue. By engineering a luminescent reporter that lights up in the presence of granzyme A activity, researchers created a stool‑based assay that directly reflects immune‑driven gut inflammation. In a study of 150 samples, the assay combined with traditional calprotectin measurements identified IBD patients more reliably than calprotectin alone, demonstrating higher sensitivity and specificity. This dual‑marker approach offers clinicians a clearer signal, reducing false positives and unnecessary follow‑up procedures.

Commercially, the technology is being shepherded through a spin‑out, IDXSense, backed by Edinburgh Innovations and European research grants. The company’s roadmap includes scaling manufacturing, securing regulatory clearance, and forging partnerships with diagnostic labs. Beyond diagnosis, the assay’s rapid readout could enable real‑time monitoring of therapeutic efficacy, paving the way for personalized treatment regimens. As the IBD diagnostics market expands, a validated, non‑invasive test could capture significant market share, driving both improved patient outcomes and new revenue streams for biotech innovators.